tiprankstipranks
Trending News
More News >

Satellos Completes Phase 1 Enrollment for DMD Drug Trial

Story Highlights
Satellos Completes Phase 1 Enrollment for DMD Drug Trial

Confident Investing Starts Here:

Satellos Bioscience ( (TSE:MSCL) ) has shared an update.

Satellos Bioscience Inc. has completed the enrollment of all four multiple-ascending dose cohorts for the Phase 1 clinical trial of its oral small molecule drug, SAT-3247, in healthy volunteers. This milestone is part of the company’s mission to deliver transformative therapies for degenerative diseases, specifically Duchenne muscular dystrophy (DMD), marking progress toward presenting Phase 1 data in 2025 and advancing the treatment as a potential novel therapy for muscle regeneration.

More about Satellos Bioscience

Satellos Bioscience Inc. is a public biotech company focused on developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders.

YTD Price Performance: -14.42%

Average Trading Volume: 123,351

Technical Sentiment Consensus Rating: Hold

Current Market Cap: $84.44M

For a thorough assessment of MSCL stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App